Examples are imatinib for chronic myelogenous leukemia (CML; Bcr/Abl translocation) (total clinical phase time = 36 months), ceritinib for ALK-positive non-small cell lung cancer (total clinical phase time = 42.7 months; approved after Phase I) and dabrafenib for BRAF-positive melanoma (total clinical development time = 47.1 months). The gene discussed is ALK; the disease is non-small cell lung carcinoma.